Should biologically-naive patients be approached differently from patients on previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?

Should biologically-naive patients be approached differently from patients on previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?

Should biologically-naïve patients be approached differently from patients who have been on a previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research Rheumatology Division Professor of Medicine University of Massachusetts Medical School Worcester, MA